tabelecleucel
Pre-clinicalCompletedDevelopment Stage
Epstein-Barr Virus (EBV) Infections
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Epstein-Barr Viremia, Lymphoma, AIDS-related, Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID), Leiomyosarcoma (LMS), Nasopharyngeal Carcinoma (NPC), Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID), Solid Organ Transplant Complications, Stem Cell Transplant Complications
— → —
About tabelecleucel
tabelecleucel is a pre-clinical stage product being developed by Atara Biotherapeutics for Epstein-Barr Virus (EBV) Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT02822495. Target conditions include Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02822495 | Pre-clinical | Completed |
Competing Products
2 competing products in Epstein-Barr Virus (EBV) Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nanatinostat in combination with valganciclovir | Viracta Therapeutics | Phase 2 | 44 |
| Durvalumab + Epacadostat | AstraZeneca | Phase 2 | 52 |